Causes and long-term course of ototoxicity in pediatric medulloblastoma and ependymoma patients – cumulative platinum and cochlear irradiation dose matter

Abstract Purpose This study aimed to define dose-dependent risk factors and thresholds for ototoxicity after cisplatin chemotherapy and radiotherapy (RT). Methods Patients from the HIT2000 trial receiving first-line treatment for medulloblastoma (MB) or ependymoma (EP) were eligible. Treatment details (incl. cochlear irradiation dose [CID]) and audiological outcome were analyzed. Ototoxicity was graded using the HIT ototoxicity grading system (HIT). Results Courses of 101 patients were analyzed. Median audiology follow-up was 6 years [range: 1.0–18.1 years]. Ototoxicity grade ≥ 1 was diagnosed for n = 66 patients (65.4%). Univariable analyses revealed differing distributions of ototoxicity regarding histology (classical medulloblastoma [CMB]: 50/65, large-cell/anaplastic medulloblastoma [LCAMB]: 3/3, desmoplastic medulloblastoma [DMB]/medulloblastoma with extensive nodularity [MBEN]: 8/12, EP: 5/21; p < 0.001), tumor localization (supratentorial: 3/9, infratentorial: 63/92; p < 0.001), metastatic status (non-metastatic disease [M0]: 46/77, metastatic disease [M+]: 20/24; p = 0.003), radiation field (craniospinal irradiation [CSI]: 59/75, local RT: 6/21, no RT: 1/5; p < 0.001), CID (p < 0.001) and cumulative cisplatinum dose (p = 0.02). Multivariable analyses confirmed the impact of cumulative cisplatinum dose (p = 0.004) and CID (p = 0.046). Receiver operating characteristic analyses defined cut-offs for high risk of ototoxicity grade ≥ 1 (cisplatinum: 70 mg/m2 body surface area [BSA], CID: 37.5 Gy): each 1 mg/m2 BSA increase in cisplatinum dose raised risk by 4%, and each 1 Gy increase in CID raised risk by 4.6%. Conclusions Ototoxicity affects a majority of children receiving adjuvant treatment for MB and EP. To avoid disabilities and negative effect on quality of life, dosage of cisplatinum and radiotherapy should be scrutinized and reduced whenever possible.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11501798/v1
Primary Topic
Hearing, Cochlea, Tinnitus, Genetics
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Causes and long-term course of ototoxicity in pediatric medulloblastoma and ependymoma patients – cumulative platinum and cochlear irradiation dose matter

Stefan M. Pfister, Stefan Rutkowski, Andre Oscar von Bueren, Dominik Sturm et al.
Research Square
Hearing, Cochlea, Tinnitus, Genetics
preprint

Causes and long-term course of ototoxicity in pediatric medulloblastoma and ependymoma patients – cumulative platinum and cochlear irradiation dose matter

Stefan M. Pfister, Stefan Rutkowski, Andre Oscar von Bueren, Dominik Sturm, Brigitte Bison, Christian Hagel, Gudrun Fleischhack, Denise Obrecht, Nicolas U. Gerber, Monika Warmuth‐Metz, Torsten Pietsch, Rolf‐Dieter Kortmann, Beate Timmermann, Katja von Hoff, Martin Mynarek, Stephan Tippelt, Annika Hardt, Rudolf Schwarz, Hans Otto Pinnschmidt, Elif Brecht
preprint en

Abstract

Abstract Purpose This study aimed to define dose-dependent risk factors and thresholds for ototoxicity after cisplatin chemotherapy and radiotherapy (RT). Methods Patients from the HIT2000 trial receiving first-line treatment for medulloblastoma (MB) or ependymoma (EP) were eligible. Treatment details (incl. cochlear irradiation dose [CID]) and audiological outcome were analyzed. Ototoxicity was graded using the HIT ototoxicity grading system (HIT). Results Courses of 101 patients were analyzed. Median audiology follow-up was 6 years [range: 1.0–18.1 years]. Ototoxicity grade ≥ 1 was diagnosed for n = 66 patients (65.4%). Univariable analyses revealed differing distributions of ototoxicity regarding histology (classical medulloblastoma [CMB]: 50/65, large-cell/anaplastic medulloblastoma [LCAMB]: 3/3, desmoplastic medulloblastoma [DMB]/medulloblastoma with extensive nodularity [MBEN]: 8/12, EP: 5/21; p < 0.001), tumor localization (supratentorial: 3/9, infratentorial: 63/92; p < 0.001), metastatic status (non-metastatic disease [M0]: 46/77, metastatic disease [M+]: 20/24; p = 0.003), radiation field (craniospinal irradiation [CSI]: 59/75, local RT: 6/21, no RT: 1/5; p < 0.001), CID (p < 0.001) and cumulative cisplatinum dose (p = 0.02). Multivariable analyses confirmed the impact of cumulative cisplatinum dose (p = 0.004) and CID (p = 0.046). Receiver operating characteristic analyses defined cut-offs for high risk of ototoxicity grade ≥ 1 (cisplatinum: 70 mg/m2 body surface area [BSA], CID: 37.5 Gy): each 1 mg/m2 BSA increase in cisplatinum dose raised risk by 4%, and each 1 Gy increase in CID raised risk by 4.6%. Conclusions Ototoxicity affects a majority of children receiving adjuvant treatment for MB and EP. To avoid disabilities and negative effect on quality of life, dosage of cisplatinum and radiotherapy should be scrutinized and reduced whenever possible.

Research Square
University of Bonn (DE), Heidelberg University (DE), University Hospital Augsburg (DE), University Hospital of Zurich (CH), University Hospital of Geneva (CH), University Medical Center Hamburg-Eppendorf (DE), Essen University Hospital (DE), Universitätsklinikum Würzburg (DE), Charité - Universitätsmedizin Berlin (DE), Leipzig University (DE)
Deutsche Kinderkrebsstiftung
Good health and well-being
Hearing, Cochlea, Tinnitus, Genetics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon